Multimodal Management With Immunotherapy, Radiation, and Surgery of Histiocytic Sarcoma Following Acute Lymphoblastic Leukemia: An Unusual Presentation of a Rare Disease

J Pediatr Hematol Oncol. 2023 Nov 1;45(8):463-466. doi: 10.1097/MPH.0000000000002751. Epub 2023 Sep 9.

Abstract

Histiocytic sarcoma (HS) is a rare neoplasm with no known cause. This sarcoma is characterized by morphology similar to that demonstrated by mature tissue histiocytes and mostly afflicts adults. HSs typically have a poor prognosis due to a rapidly progressive clinical course. Our patient's case was unique due to its presentation four years after completion of treatment for B-cell acute lymphoblastic leukemia. The patient experienced progression with initial therapy for HS. With dual immunotherapy and radiation, however, the patient has remained clinically stable without detectable disease. Immunotherapy may be a successful and tolerable therapeutic option for histiocytic disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Histiocytic Sarcoma* / therapy
  • Humans
  • Immunotherapy
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
  • Rare Diseases